The Science
Physiologic Insulin Resensitization (PIR) is an innovative, multi-patented approach that holds FDA approval for the infusion device and infusion biologic. Through PIR, insulin is administered as a hormone rather than a drug, addressing the primary cause of diabetes and insulin resistance, which is metabolic failure. By using insulin in a manner that biomimics normal physiology, we are better able to reduce insulin resistance, which helps blood sugar more readily enter each cell and be converted into energy.
By increasing cellular energy through PIR, damaged tissues and organ cells can grow, repair and regenerate. In many cases, this approach has shown the ability to stabilize, and in some instances, reverse, complications of diabetes and other metabolic disorders.
​
Studies have shown:
elimination or significant improvement in neuropathy
improvement in at least one diabetic complication
HbA1c reduction
Medication reduction
Source: Schull Institute Study Insulin Infusion Therapy on Diabetic Complications (Oct. 27, 2015).
Peer-Reviewed Publications
Learn more about the science behind PIR in peer-reviewed publications.
